Although clinical trials of potential disease-altering therapies (e.g., anti-tau antibodies, tau aggregation inhibitors) are currently underway (Boxer et al., 2013; Tsai and Boxer, 2016; Mis et al., 2017; Logroscino et al., 2019; Panza et al., 2020; Huang et al., 2023), the significant degree of clinical, pathological and genetic heterogeneity observed in FTD hinders the development of sensitive and specific biomarkers that would allow for targeted recruitment of groups at highest risk for clinical/cognitive decline (Katzeff et al., 2022). This evidence concerns the gene MAPT and Mental deterioration.